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Introduction
Methotrexate (MTX) is a cornerstone and safe disease-
modifying anti-rheumatic drug (DMARD) in the treat-
ment of juvenile idiopathic arthritis (JIA). Despite its
safety, MTX intolerance occurs frequently, leading to
non-compliance, thus hampering efficacy and potentially
leading to early discontinuation.
Objectives
The aim of this study was to construct a risk model to
predict MTX intolerance.
Methods
In a large, prospective JIA cohort, potential predictors
(clinical variables and single nucleotide polymorphisms)
were determined at the time of MTX start. The Metho-
trexate Intolerance Severity Score was employed to mea-
sure MTX intolerance in the first year of treatment. MTX
intolerance was most prevalent at 6 or 12 months after
MTX start. This was defined as the outcome for the pre-
diction model. The model was developed in 152 patients
using multivariate logistic regression analysis. It was sub-
sequently internally validated using bootstrapping.
Results
The prediction model included the following predictors:
JIA subtype, antinuclear antibody, parent/patient assess-
ment of pain, Juvenile Arthritis Disease Activity Score-27,
thrombocytes, alanine aminotransferase and creatinine.
The model classified 77.5% of patients correctly, changing
to 66.7% after internal validation by bootstrapping. The
prediction model was transformed into a risk score (range
0-17). At an optimal cut-off of ≥6, sensitivity was 82.0%,
specificity 56.1%, positive predictive value was 58.7%
and negative predictive value 80.4%.
Conclusion
The prediction model combined routine clinical variables
and showed good predictive power to detect MTX intol-
erance. This easy-to-use tool could assist clinicians in
identifying patients at risk to develop MTX intolerance.
Consequently, clinicians can monitor them closely and
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